Regulatory Issues of Importance to Developing Anti-HIV Therapeutics

Abstract

In the United States, before clinical trials with new drugs can proceed, an Investigational New Drug (IND) application must be submitted to the Food and Drug Administration. Applications for drugs intended for the treatment of HIV-related diseases are reviewed by the Division of Anti-Viral Drug Products (DAVDP) within the Center for Drug Evaluation and Research. IND applications must contain adequate preclinical studies to support the safety of the proposed clinical trials. Essential for demonstrating safety are animal toxicology studies in which the drug has been administered in doses, by the route(s) of administration, and over a length of time equivalent to the corresponding parameters proposed for clinical trials. Reproductive toxicology/teratology studies should be conducted early in the development of the drug. Other nonclinical toxicology studies, such as carcinogenicity bioassays, are usually conducted concurrently with clinical trials. The DAVDP has developed a Pre-IND program to assist sponsors in preparing the best preclinical research to support the development of new drugs.

Keywords

Pre-Investigational New Drug (pre-IND) Program

References

Anonymous (1993). Points to Consider in the Preparation of IND Applications for New Drugs Intended for the Treatment of HIV-Infected Individuals (P-1). DAVDP, Center for Drug Evaluation and Research, FDA.

Anonymous (1993). Points to Consider in the Preclinical Development of Antiviral Drugs (P-2) . DAVDP, Center for Drug Evaluation and Research, FDA.

Anonymous (1993). Points to Consider in the Preclinical Development of Immunomodulatory Drugs for the Treatment of HIV Infection and Associated Disorders (P-3). DAVDP, Center for Drug Evaluation and Research, FDA.

Anonymous (1993). Points to Consider in the Immunotoxicology Evaluation of New Drugs Intended for the Treatment of HIV Infection and Related Disorders (P-4). DAVDP, Center for Drug Evaluation and Research, FDA.

Anonymous ( 1993). Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed. Reg. 58 (139, Thursday, July 22).

Anonymous ( 1994). Guideline on detection of toxicity to reproduction for medicinal products. Fed. Reg. 59 (183, Thursday, September 22).

Manson JM and Kang YJ (1994). Test methods for assessing female reproductive and developmental toxicology. In AW Hayes (ed), Principles and Methods of Toxicology, 3rd ed. Raven Press, New York, pp. 989-1037.

Peck CC , Barr WH , Benet LZ , Collins J. , Desjardins RE , Furst DF , Harter JG , Levy G. , Ludden T. , Rodman JH , Sanathanan L. , Schentag JJ , Shah VP , Sheiner LB , Skelly JP , Stanski DR , Temple RJ , Viswanathan CT , Weissinger J. , and Yacobi A. (1992). Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharmaceut. Res. 9: 826-833.

Sperling RS and Stratton P. (1992). Treatment options for human immunodeficiency virus-infected pregnant women. Obstet. Gynecol. 79: 443-448.

10.

Vocci F. and Farber T. (1988). Extrapolation of animal toxicity data to man. Reg. Toxicol. Pharmacol. 8: 389-398.

11.

Voisin EM , Ruthsatz M. , Collins JM , and Hoyle PC (1990). Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Reg. Toxicol. Phartnacol . 12: 107-116.